

Mario Salvi, *Fondazione IRCCS Cà Granda Milan*

Dr. Salvi graduated in Medicine and trained in Endocrinology in Italy. He carried out post-doc research projects at McGill University in 1985-91 with specific focus on the pathogenesis of Graves' disease and orbitopathy. He continued his work in Parma until 2001 and from 2002 at the University of Milan. He is heading the Graves' Orbitopathy Center of the Fondazione IRCCS Cà Granda, Milan, which he founded in 2003 and is currently the Chairman of EUGOGO (European Group On Graves' Orbitopathy). He has pioneered immunotherapy and has been carrying out clinical studies with rituximab, the anti-BAFF belimumab, the anti-IGF-1 receptor antibody teprotumumab, and the anti-IL-6 receptor antibody tocilizumab in Graves' orbitopathy, in addition to multicenter trials carried out within EUGOGO. He has contributed to the book: "Graves' Orbitopathy: a multidisciplinary approach" edited by EUGOGO, and has co-authored the ATA/ETA Consensus Document on Management of Graves' orbitopathy. He has published more than 240 papers (H-Index 49) and gave more than 200 scientific communications and invited lectures at international meetings.